Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Fox Corp Class B (FOX) Price & Performance

Cassava Sciences IncTrade
Fox Corp Class BTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Fox Corp Class B — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Fox Corp Class B trades at $54.96 (market cap $24.58B). The key difference: Fox Corp Class B is far larger — about 514.8× Cassava Sciences Inc's market cap, and Fox Corp Class B pays a 1.05% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAFOX
Market Cap
$47.75M$24.58B
Sector
HealthMedia
52-Week High
$4.64$67.76
52-Week Low
$0.87$44.39
Enterprise Value
-$34.93M$27.94B
Dividend Yield
1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Fox Corp Class B

FOX trades at $56.33, down 1.23% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent earnings beats and strong 2025 results, including $16.3B revenue and $2.26B net income, support a P/E of 14.41. Positive news includes Tubi's partnership with Gracenote for CTV advertising growth (PRNewswire, Aug 12, 2026).

The outlook is positive with robust ad momentum and digital expansion, though risks include cyclical advertising exposure and high RSI suggesting near-term pullback potential. Analyst consensus leans neutral with 42.86% buy ratings, indicating cautious optimism for long-term holders amid competitive media pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Fox Corp Class B

Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.

Read more on FOX